


Supplementary Figures

Figure 1S. The effect of combinations of salmochelin S4 or enterobactin with lincomycin (A) and salmochelin S4 with linezolid (B) on the growth *S. aureus* strain ATCC 25923. Sal - salmochelin, Ent - enterobactin, Linco – lincomycin, Lin – linezolid, Growth control - without siderophore and antibiotic.

A.



B.





Figure 2S. Enterobactin (A) and salmochelin S4 (B) inhibits the growth of VRE clinical strain 195 in a dose- dependent manner. Sal - salmochelin, Ent - enterobactin, Growth control - without siderophore. Similar results were observed in other VRE clinical strains.

A.



B.






Figure 3S. The inhibitory activity of enterobactin and salmochelin S4 on Gram-negative bacteria. (A) *Klebsiella pneumoniae* carbapenemase clinical strain (B)

Acinetobacter baumannii clinical strain (C) *Pseudomonas aeruginosa* ATCC 9027
(D) Uropathogenic *Escherichia coli* CFT073. Sal - salmochelin, Ent – enterobactin,
Growth control - without siderophore.


A.



B.



C.



D.

